Cork, Ireland, May 2022 – Metabolomic Diagnostics is delighted to welcome Dr Greg Fitzgibbon to the team as Clinical Laboratory Director. Greg brings with him a wealth of clinical laboratory experience from the NHS, CLIA and previous laboratory directorships. His technical and operational knowledge has been instrumental in the development of multiple In Vitro Diagnostics (IVDs) in areas like genetic disease testing, women’s health, as well as prenatal and companion diagnostics.
Greg holds a Certificate of Qualification for the Clinical Laboratory Improvements Amendments (CLIA) as issued by the New York State Department of Health. In Metabolomic Diagnostics Greg will contribute his vast operational and strategic clinical laboratory expertise to support the company’s commercialisation efforts and the build out of the company’s product portfolio.
Greg has previously fulfilled roles as COO, Clinical Director and IVD Product Development Manager in multiple Molecular Diagnostic Companies. He successfully led operations teams performing product development and manufacturing under ISO 13485. Greg holds a Doctorate in Molecular Genetics, he is a HCPC registered Clinical Scientist and is a Diplomate member of the Royal College of Pathologists. Greg has over 8 years clinical laboratory management experience within the NHS; in this capacity he was also overseeing the evaluation, implementation, verification, and validation of new technologies for clinical use. He has also an entrepreneurial track record having been involved in the inception, growth and development of various Biotechnology businesses including Syngenta, Gen-Probe, Hologic, Epistem, Elucigene Diagnostics, Yourgene Health, MyHealthChecked.